Merseburger Offers PRESIDE Trial Overview of Continuous Enzalutamide in mCRPC

Video

Axel Merseburger, MD, PhD, spoke key results of the PRESIDE trial, which examined continuous enzalutamide to treat patients with metastatic castration-resistant prostate cancer and progressive disease.

In an interview with CancerNetwork® during the 2022 Genitourinary Cancers Symposium, Axel Merseburger, MD, PhD, chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, discussed the PRESIDE trial (NCT02288247) of enzalutamide (Xtandi) vs matched placebo plus docetaxel and prednisone for men with progressive metastatic castration-resistant prostate cancer. The study was conducted to determine a continued benefit of the androgen receptor inhibitor after disease progression.

Transcript:

The PRESIDE trial showed the clinical benefit of continuing enzalutamide to post-progression [treatment]. This trial was a randomized phase 3b trial in advanced metastatic castration-resistant prostate cancer, with the primary end point progression-free survival [PFS].

Besides the primary end point of PFS which was met with a 28% benefit for the combination of enzalutamide, docetaxel, and prednisone compared with the placebo, docetaxel, and prednisone [HR, 0.72; 95% CI, 0.53-0.96; P = .027]. We could demonstrate that there was a greater decrease in PSA from baseline to week 13 in the enzalutamide group at –37.12% compared with 9.11% in the placebo group.

Reference

Merseburger A, Attard G, Boysen G, et al. A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE. J Clin Oncol. 2022;40(suppl 6):15. doi: 10.1200/JCO.2022.40.6_suppl.015

Recent Videos
4 experts in this video
4 experts in this video
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content